Filter by
 

Type of content

Publication date

Keywords

Keywords

Target audience

Risk assessments

Displaying 21 - 36 of 36

Publications

Risk Assessment Report of a new psychoactive substance: 1-cyclohexyl-4-(1,2-diphenylethyl)piperazine (MT-45)

01.11.2014

This report presents the data and findings of the risk assessment on the new psychoactive substance, MT-45, that was conducted by the Scientific Committee of the EMCDDA. Concerns over the availability and use of this stimulant drug in the European Union led to an assessment of the health and social...

Publications

Report on the risk assessment of 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe) in the framework of the Council Decision on new psychoactive substances

01.05.2014

SThis report presents the data and findings of the risk assessment on the new psychoactive substance, 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe), that was conducted by the Scientific Committee of the EMCDDA. Concerns over this hallucinogenic drug in the European Union...

Publications

Report on the risk assessment of 1-(1,3-benzodioxol-5-yl)-2-(pyrrolidin-1-yl)pentan-1-one (MDPV) in the framework of the Council Decision on new psychoactive substances

01.05.2014

This report presents the data and findings of the risk assessment on the new psychoactive substance, 1-(1,3-benzodioxol-5-yl)-2-(pyrrolidin-1-yl)pentan-1-one (MDPV), that was conducted by the Scientific Committee of the EMCDDA. Concerns over this stimulant drug in the European Union led to an...

Publications

Report on the risk assessment of 3,4-dichloro-N-{[1-(dimethylamino)cyclohexyl]methyl}benzamide (AH-7921) in the framework of the Council Decision on new psychoactive substances

01.05.2014

This report presents the data and findings of the risk assessment on the new psychoactive substance, 3,4-dichloro-N-{[1-(dimethylamino)cyclohexyl]methyl}benzamide (AH-7921), that was conducted by the Scientific Committee of the EMCDDA. Concerns over this synthetic opioid in the European Union led...

Publications

Report on the risk assessment of 2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone (methoxetamine) in the framework of the Council Decision on new psychoactive substances

01.05.2014

This report presents the data and findings of the risk assessment on the new psychoactive substance, 2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone (methoxetamine), that was conducted by the Scientific Committee of the EMCDDA. Concerns over this issociative drug in the European Union led to an...

Publications

Report on the risk assessment of 5-(2-aminopropyl)indole (5-IT) in the framework of the Council Decision on new psychoactive substances

01.01.2014

This report presents the data and findings of the risk assessment on the new psychoactive substance, 5-(2-aminopropyl)indole (5-IT), that was conducted by the Scientific Committee of the EMCDDA. Concerns over the availability and use of this stimulant drug in the European Union led to an assessment...

Publications

Report on the risk assessment of 4-methylamphetamine (4-MA) in the framework of the Council Decision on new psychoactive substances

01.01.2014

This report presents the data and findings of the risk assessment on the new psychoactive substance, 4-methylamphetamine, that was conducted by the Scientific Committee of the EMCDDA. Concerns over the availability and use of this stimulant drug in the European Union led to an assessment of the...

Publications

Report on the risk assessment of mephedrone in the framework of the Council Decision on new psychoactive substances

01.05.2011

This publication presents the summary findings and the conclusions of the risk assessment on mephedrone, carried out by the EMCDDA’s extended Scientific Committee, with participation of additional experts from the European Commission, Europol and the EMA. The risk assessment report, which was...

Publications

Report on the risk assessment of BZP in the framework of the Council decision on new psychoactive substances

01.02.2009

This publication presents the findings of the formal risk assessment on BZP, produced in 2007 by the Scientific Committee of the EMCDDA, with participation of additional experts from the European Commission, Europol and the EMEA. The risk assessment report, which was submitted to the European...

Publications

Report on the risk assessment of TMA-2 in the framework of the joint action on new synthetic drugs

01.05.2004

The risk-assessment report on the synthetic drug TMA-2 was submitted by the EMCDDA to the European Council and Commission on 4 April 2003. The report was drawn up at a meeting in Lisbon from 31 March to 1 April under the auspices of an enlarged EMCDDA Scientific Committee. The drug was singled out...

Publications

Report on the risk assessment of 2C-I, 2C-T-2 and 2C-T-7 in the framework of the joint action on new synthetic drugs

01.05.2004

The risk-assessment reports on the synthetic drugs 2C-I; 2C-T-2 and 2C-T-7 were submitted by the EMCDDA to the European Council and Commission on 4 April 2003. The reports were drawn up at a meeting in Lisbon from 31 March to 1 April under the auspices of an enlarged EMCDDA Scientific Committee....

Publications

Report on the risk assessment of PMMA in the framework of the joint action on new synthetic drugs

01.03.2003

The report assesses the risks of PMMA, especially in association with the already controlled substance PMA (para-methoxyamphetamine). PMMA, is an amphetamine-like substance very close to PMA, and is almost exclusively sold in tablet form in combination with the latter and consumed as ‘ecstasy’. It...

Publications

Report on the risk assessment of ketamine in the framework of the joint action on new synthetic drugs

01.06.2002

Since the mid-1990s, ketamine – widely used in human and veterinary medicine for 30 years – has been surfacing as a recreational drug. Concern over ketamine centres on its unpredictability in producing ‘near-death’ experiences. The risk-assessment exercise was carried out in 2000 in the framework...

Publications

Report on the risk assessment of GHB in the framework of the joint action on new synthetic drugs

01.06.2002

Since the mid-1990s, GHB – widely used in human and veterinary medicine for 30 years – has been surfacing as a recreational drug. Some EU countries have reported worries over GHB’s surreptitious use in sexual assaults. Although the extent of this is unknown, the EMCDDA and its risk-assessment...

Publications

Report on the risk assessment of 4-MTA in the framework of the joint action on new synthetic drugs

01.10.1999

An enlarged EMCDDA Scientific Committee met from 18–19 May 1999 in Lisbon to assess the risks of the synthetic drug 4-MTA (4-methylthioamphetamine) in the framework of the Joint action on new synthetic drugs. The Committee's tasks were to assess the health and social risks of the substance and the...

Publications

Report on the risk assessment of MBDB in the framework of the joint action on new synthetic drugs

01.06.1999

On 27 February 1998, the drug MBDB (N-methyl-1-(1,3-benzodioxol- 5-yl)-2-butanamine) became the first new synthetic drug to be submitted for risk assessment under the terms of the Joint Action concerning the information exchange, risk assessment and control of new synthetic drugs adopted on 16 June...

Loading